Loading…
USA Quick Meds was cited for introducing unapproved and misbranded opioids and benzodiazepines into interstate commerce through its website in violation of the Federal Food, Drug, and Cosmetic Act (sections 301(a), 301(d), 301(k), 503(b), and 505(a)). The FDA emphasized the significant public health risks posed by internet sales of these controlled substances, particularly given the ongoing opioid epidemic and the dangers of benzodiazepine abuse and polysubstance overdose deaths. The company's unapproved drugs lacked the safety and effectiveness assurances required for FDA-regulated products.